Amneal announces new biosciences unit headed by pharmacy vet

EDGEWATER, N.J. — Amneal Pharmaceuticals announced Tuesday that it would be opening a new biosciences unit, Amneal Biosciences, which will be focused on commercializing specialty pharmaceuticals like oncologics, injectables and biosimilars.

“Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to healthcare institutions and professionals that we deliver to our existing retail customers,” Amneal co-CEO and chairman Chirag Patel said. “Our experienced Amneal Biosciences team provides the high degree of expertise these specialty products require.”

Amneal also announced that it would be appointing Charles Lucarelli, who joined the company in March, as Amneal Biosciences’ president. Before joining Amneal, Lucarelli spent 37 years at Memorial Sloan-Kettering Cancer Center, where he was director of pharmacy for 25 years.

“It is an honor to serve as President of Amneal Biosciences and lead this talented group of professionals at such a pivotal time in our company’s evolution,” Lucarelli said.  “Our robust product pipeline will bring the Amneal legacy of quality and customer service to a segment in need of therapeutic affordability and reliable supply.”